Table 3 HR value for NSCLC subgroups according to histology subtypes and stages

From: Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis

Subgroup

Studies

Patients

Fixed effect HR (95% CI)

Heterogeneity test

Ramdom effect HR (95% CI)

Adenocarcinoma

n=4

258

2.45 (1.66–3.64)

P=0.26

 

Nonsquamous carcinoma

n=3

158

2.47 (1.32–4.57)

P=0.90

 

Stage I

n=4

783

1.56 (1.26–1.93)

P=0.17

 

Stage I–II

n=4

437

1.16 (0.82–1.66)

P=0.21

 

Stage I–III

n=6

533

1.79 (1.40–2.28)

P=0.04

1.82 (1.26–2.64)

Back to article page